Enteral Nutrition in the Management of Pediatric and Adult Crohn's Disease
Abstract
Genetic and environmental factors are thought to profoundly influence the pathophysiology of Crohn's disease (CD). Changes in dietary and hygiene patterns affect the interactions between the immune system and environment. The gut microbiome is responsible for mediating host immune response with significant dysbiosis observed in individuals with CD. Diet therapy using exclusive enteral nutrition (EEN) has been studied as primary therapy for the management of CD. EEN may cultivate the presence of beneficial microbiota, improve bile acid metabolism, and decrease the number of dietary microparticles possibly influencing disease and immune activity. In this review, we will address the current evidence on EEN in the management of adult and pediatric CD. In adults, EEN appears to be moderately beneficial for the induction of remission of CD; however, its use is understudied and underutilized. Stronger evidence is in place to support the use of EEN in pediatric CD with the added benefit of nutrition support and steroid-sparing therapy during the growth phase. Overall, EEN is an established therapy in inducing CD remission in the pediatric population while its role as primary therapy of adult Crohn's disease remains to be defined.
Hansen, T., & Duerksen, D. (2018). Enteral Nutrition in the Management of Pediatric and Adult Crohn’s Disease. Nutrients, 10(5), 537. https://doi.org/10.3390/nu10050537
In adults, EEN appears to be moderately beneficial for the induction of remission of CD; however, its use is understudied and underutilized. Stronger evidence is in place to support the use of EEN in pediatric CD with the added benefit of nutrition support and steroid-sparing therapy during the growth phase. Overall, EEN is an established therapy in inducing CD remission in the pediatric population while its role as primary therapy of adult Crohn's disease remains to be defined.
Support our Mission
Your donation will help us to enhance the well-being and health outcomes of patients with IBD.
Donate